MTOR and cancer: The shift from oxidative to predominantly glycolytic metabolism often requires the activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway, one of the most ubiquitous abnormalities in cancer [98].